Quick Answer
M. genitalium is an emerging bacterial STI associated with urethritis and cervicitis. Treatment is challenging due to antibiotic resistance, often requiring multiple sequential courses. It is not included in standard STI panels.
- Emerging bacterial STI
- Resistance: high rates to azithromycin and fluoroquinolones
- Treatment: sequential doxycycline then moxifloxacin
- Not on standard panels: must be specifically requested
Context Most Pages Skip
Mycoplasma genitalium is the STI you probably have not heard of, but it is increasingly recognized as a cause of persistent urethritis.
Key Facts
M. genitalium is not included in standard STI panels. It requires a specific NAAT test. Treatment is challenging due to antibiotic resistance, with current guidelines recommending sequential therapy: doxycycline 7 days followed by moxifloxacin 7 days.
⚕️ This page is educational and does not replace advice from a licensed clinician. If you may have been exposed to an STI, get tested — most infections are manageable, and many are fully curable.
Sources & Further Reading
- CDC — Sexually Transmitted Infections
- CDC STI Treatment Guidelines
- WHO — Sexually transmitted infections fact sheet
- MedlinePlus — Sexually Transmitted Diseases
Figures reflect CDC surveillance and WHO estimates; they are population statistics, not personal risk predictions.